PRINCETON, N.J.--(BUSINESS WIRE)-- UroGen Pharma Ltd. (URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today ...

A phase 2 trial evaluated the effectiveness and safety of neoadjuvant intravesical mitomycin-C instillation in patients with urothelial non-muscle invasive bladder cancer.

The FDA approved mitomycin intravesical solution (Zusduri) as a nonsurgical option for recurrent low-grade, intermediate-risk non-muscle invasive bladder cancer (NMIBC). The product won the indication ...

To reduce papillary tumor recurrence, optimized intravesical mitomycin C combined with fluorescence blue-light cystoscopy shows promise. Fluorescence blue-light cystoscopy along with optimized ...

Probability of Remaining Event-Free at 24 Months by Kaplan-Meier Analysis After Achieving Complete Response at Three Months ...

The PDUFA target date was set for June 13, 2025. The Food and Drug Administration (FDA) announced that it has accepted the New Drug Application (NDA) for UGN-102 for intravesical solution for the ...

UGN-102 could become the first FDA-approved treatment for low-grade intermediate-risk non-muscle-invasive bladder cancer, with a PDUFA goal date of June 13, 2025. The phase 3 ENVISION trial ...

SPADE: Design of a real-world observational study of avelumab first-line (1L) maintenance in advanced urothelial carcinoma (UC) in the Asia-Pacific (APAC) region. This is an ASCO Meeting Abstract from ...

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, ...

The 2026 SESAUA annual meeting featured a bladder cancer session and a presentation by Dr. William Huang discussing the ...